EP Patent

EP2359813A1 — Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid

Assigned to Ratiopharm GmbH · Expires 2011-08-24 · 15y expired

What this patent protects

The present invention relates to a pharmaceutical composition comprising Dasatinib as active pharmaceutical ingredient.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising Dasatinib as active pharmaceutical ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2359813A1
Jurisdiction
EP
Classification
—
Expires
2011-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.